A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Latest Information Update: 30 Oct 2013
Price :
$35 *
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 30 Oct 2013 New trial record